Hennion & Walsh Asset Management, Inc. Ngm Biopharmaceuticals Inc Transaction History

Hennion & Walsh Asset Management, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 17, 2024	BUY	$1.17 - $1.92 $5,499 - $9,024	4,700 Added 7.13%	70,636 $112,000
Q4 2023 Jan 10, 2024	BUY	$0.6 - $1.31 $4,841 - $10,570	8,069 Added 13.94%	65,936 $56,000
Q3 2023 Oct 27, 2023	BUY	$1.05 - $3.37 $2,412 - $7,744	2,298 Added 4.14%	57,867 $61,000
Q2 2023 Aug 09, 2023	SELL	$2.44 - $4.53 $3,652 - $6,781	-1,497 Reduced 2.62%	55,569 $144,000
Q1 2023 Apr 20, 2023	SELL	$3.72 - $5.4 $6,707 - $9,736	-1,803 Reduced 3.06%	57,066 $233,000

Q4 2022 Jan 12, 2023	SELL	$3.41 - $12.93 $396,630 - $1.5 Million	-116,314 Reduced 66.4%	58,869 $296,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $73,601 - $103,298	5,846 Added 3.45%	175,183 $2.29 Million
Q2 2022 Jul 19, 2022	SELL	$10.58 - $17.5 $814,501 - $1.35 Million	-76,985 Reduced 31.25%	169,337 $2.17 Million
Q1 2022 Apr 26, 2022	SELL	$13.81 - $18.6 $144,121 - $194,109	-10,436 Reduced 4.06%	246,322 $3.76 Million
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $349,204 - $445,508	-20,232 Reduced 7.3%	256,758 $4.55 Million
Q3 2021 Nov 12, 2021	SELL	$20.15 - $26.19 $190,780 - $247,966	-9,468 Reduced 3.31%	276,990 $5.82 Million
Q2 2021 Aug 13, 2021	BUY	$15.06 - $30.03 $400,852 - $799,308	26,617 Added 10.24%	286,458 $5.65 Million
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $6.49 Million - $8.3 Million	259,841 New	259,841 $7.55 Million

36.8M

1.1K

200

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.